Michael Morin is “an expert on pharmaceutical and biologics matters, he is a persuasive option in DC for life sciences clients.” He is praised as “a natural-born leader” and as “insightful and downright clever as they come” with the ability to “succinctly capture complicated ideas and translate it all into a simple message.” IAM Patent 1000 2016-2017

Michael A. Morin

Washington, D.C. | Chicago
  • 555 Eleventh Street, NW
  • Suite 1000
  • Washington, D.C. 20004-1304
  • USA

Michael Morin is a partner in the Intellectual Property Litigation Practice. He is a first chair litigator with extensive trial and appellate experience relating to intellectual property matters.

Mr. Morin’s practice focuses primarily on patent litigation at both the trial and appellate court levels. Mr. Morin’s cases have involved a comprehensive scope of technical subjects including:

  • Medical Devices
  • Software
  • Pharmaceuticals
  • Biologics
  • Consumer Products
  • Computer Games
  • Sporting Goods

Mr. Morin is an experienced first-chair trial lawyer in both federal district court litigations and arbitrations. He is also an experienced appellate advocate, having argued at the United States Court of Appeals for the Federal Circuit on numerous occasions.

Mr. Morin has substantial experience in all aspects of patent litigation, across a wide range of technologies. He has gained particular experience in pharmaceutical and biologics litigation in recent years, having led multiple litigations involving several of the world’s best-selling drugs. He also has significant experience litigating software patents, having defended cases involving some of the best-selling business software in the world. Likewise, he has litigated multiple cases involving top of class, household name consumer products.

Mr. Morin is recognized as a leading IP litigation lawyer by numerous industry publications. He was recognized in Intellectual Asset Management’s “Patent 1000 – The World’s Leading Patent Practitioners” guide (2015-2017), Who’s Who Legal — Patents (2016). He is also recognized for his work across the life sciences industry and was recommended by The Legal 500 US (2017) and named a “Life Sciences Star” for IP litigation by Legal Media Group and Euromoney (2016).

In addition, Mr. Morin advises clients regarding their intellectual property portfolios and strategies, assists with licensing issues, and renders opinions advising clients of their legal positions and responsibilities. He also devotes considerable time to pro bono activities, representing disabled veterans in civil matters and indigent defendants in criminal cases. Mr. Morin currently serves on the firm’s Recruiting Committee.

Mr. Morin is a faculty member of the Trial Advocacy College at the University of Virginia, where he teaches trial skills to lawyers from around the United States. He is also heavily involved in the Sedona Conference, where he is leading a working group on parallel district court and PTO proceedings. In addition, he frequently lectures on litigation matters at conferences hosted by the Federal Circuit Bench and Bar, the American Bar Association, the American Intellectual Property Law Association, the American Law Institute-American Bar Association, the Patent Resource Group and the Practising Law Institute.

Prior to joining Latham, Mr. Morin was a partner in the patent litigation practice at a global intellectual property law firm.

Mr. Morin’s representative experience includes:

  • Lead counsel for AbbVie in multiple litigations involving Humira®, the world’s leading selling drug, in which the Federal Circuit recently affirmed the trial court’s finding of invalidity after a week-long bench trial
  • Lead counsel for AbbVie in multiple litigations involving top-selling drugs for the treatment of Hepatitis C
  • Lead counsel for AbbVie in multiple patent infringement litigations involving its market-leading Zemplar® product*
  • Represented Abbott in a series of litigations involving its market-leading coronary stents, resulting in a US$400 million settlement*
  • Lead counsel for Abbott in three separate arbitrations, prevailing in all three cases and recovering attorney fees in two of them*
  • Responsible for coordinating Abbott’s successful worldwide defense in a series of patent litigations involving stents
  • Lead counsel for 3M in multiple litigation matters, including a case involving its market-leading painter’s tape, a case involving combat helmets and a case involving adhesive bandages*
  • Lead counsel for SAP in multiple patent infringement cases involving its market-leading business software*
  • Lead counsel for Ameriprise in multiple patent infringement litigation matters involving financial services*

*These matters were handled prior to Mr. Morin joining Latham & Watkins.

Thought Leadership
  • Chapter Editor, of “The Sedona Conference Commentary on Patent Litigation Best Practices: Parallel USPTO Proceedings,” 2014
  • Co-author, “Hang Together or Hang Separately: The Common Interest Privilege,” Practising Law Institute, July 14, 2010
  • Co-author, “Processing Grain: Lost-Profits Damages and Some Practical Considerations for the Patent Litigator,” IP Litigator, July/August 2005
  • Co-author, “Troubles for Most-Favored Licenses,” les Nouvelles, March 1998
  • Co-author, “An Overlooked Weapon in Antisubmarine Warfare,” Patent World, 1995
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.